Willis Towers Watson (WLTW) CMD 2024 summary
Event summary combining transcript, slides, and related documents.
CMD 2024 summary
12 Jan, 2026Strategic direction and future plans
Launched a refreshed strategy focused on accelerating performance, enhancing efficiency, and optimizing the business portfolio, building on a successful three-year transformation.
Emphasizing organic and inorganic growth, with a disciplined approach to M&A, especially in broking and high-growth, high-margin areas.
Announced reentry into the treaty reinsurance broking market via a joint venture with Bain Capital, aiming for long-term value creation and capital efficiency.
Targeting expansion in the middle market, high-growth geographies, and adjacencies, leveraging AI, automation, and proprietary data.
Portfolio optimization includes divesting non-core assets like TRANZACT and investing in scalable, recurring solutions.
Financial guidance and performance outlook
Achieved 5% organic revenue CAGR since 2021, with margin expansion and double-digit EPS CAGR.
Targeting mid-single-digit organic revenue growth long-term, with 2024 revenue expected to exceed $9.9B.
Projecting annual margin expansion, with R&B targeting 100 basis points per year over the next three years and continued margin improvement in HWC.
Free cash flow margin reached 17.5% (normalized) in 2023, with further improvement expected as transformation and divestitures conclude.
Capital allocation prioritizes share repurchases, disciplined M&A, and investment in talent and technology, maintaining a leverage ratio of 2–2.5x and over $6.7B in share repurchases since 2021.
Business segment developments
HWC segment delivered strong, consistent growth and margin expansion, with high client retention and a focus on recurring revenue and cross-selling.
Health is fastest growing, wealth is expanding through DB and DC solutions, and career is shifting to more recurring, less discretionary revenue.
BD&O remains a platform for growth post-TRANZACT, focusing on high-margin, scalable outsourcing and marketplace solutions.
R&B segment achieved high-single digit organic growth, driven by specialization, digitalization, and global broking platform rollout, with specialty lines outpacing the rest.
Both segments leverage cross-selling, integrated solutions, and recurring revenue models to deepen client relationships and drive sustainable growth.
Latest events from Willis Towers Watson
- Organic growth and margin expansion drove strong results despite divestiture impacts.WLTW
Q4 20253 Feb 2026 - Q2 2024 delivered 6% organic growth, margin expansion, and raised 2024 guidance.WLTW
Q2 20242 Feb 2026 - Q3 saw 6% revenue growth, margin gains, and a $1.67B loss from TRANZACT sale charges.WLTW
Q3 202417 Jan 2026 - 5% organic growth, margin gains, $473M savings, and $1.5B buyback planned for 2025.WLTW
Q4 20248 Jan 2026 - $1.3B acquisition leverages advanced tech and talent for $35M in synergies and U.S. growth.WLTW
M&A Announcement10 Dec 2025 - 2025 AGM to vote on directors, auditors, executive pay, share issuance, and pre-emption rights.WLTW
Proxy Filing1 Dec 2025 - Annual meeting covers director elections, pay, and auditor ratification.WLTW
Proxy Filing1 Dec 2025 - 5% organic growth and margin expansion offset TRANZACT sale; net income up 23%.WLTW
Q1 20251 Dec 2025 - Q2 2025 saw 5% organic growth, 20% EPS rise, and robust margin expansion amid strong segment results.WLTW
Q2 20255 Nov 2025